Better Health. Better Life.

Dr. Orly Yadid-Pecht Joins Advisory Board Of M Pharmaceutical, Inc.

Dr. Orly Yadid-Pecht, IEEE Fellow (2007), SPIE Fellow (2015) and 2006 ITHEA Information and Communication Technologies winner brings 20-years of experience in sensors, neural networks and micro-nano system implementations to Canadian biomedical technology company.

VANCOUVER, B.C., CANADA ( JUNE 17, 2015) - M Pharmaceutical Inc., (CSE:MQ, OTCQB:MPHMF), (the "Company") a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, has added internationally-recognized specialist in sensors and micro-nano systems technology Dr. Orly Yadid-Pecht to its Advisory Board, the Company announced today.

"As we enter the key phases of product development and prepare to bring our biomedical technologies to market, we are relying increasingly on the broad base of expertise and experience of our senior leadership team and Advisory Board," said Dr. Martin Mintchev, President & Chief Executive Officer of M Pharmaceutical, Inc. "I'm particularly delighted to have Dr. Yadid-Pecht on our Advisory Board and know how much added value she will bring to the development and launch of technologies such as the e-Mosquito, our gastro-intestinal neurostimulators and pseudobezoars. We're only stronger with her kind of international credentials in several of the fields that are at the heart of our product technologies."

Dr. Yadid-Pecht has an impressive resume spanning her education at Technion - Israeli Institute of Technology and work at the Jet Propulsion Laboratory (JPL/ California Institute of Technology (Caltech) as a National Research Council (NRC) Fellow in the United States, along with her tenures at Ben-Gurion University and the University of Calgary.

She received her B.Sc. from the Electrical Engineering Department at Technion, where she went on to complete her M.Sc. in 1990 and D.Sc. in 1995, respectively. She was an NRC research fellow from 1995-1997 in the areas of Advanced Image Sensors at the Jet Propulsion Laboratory (JPL)/California Institute of Technology (Caltech). In 1997 she joined Ben-Gurion University in Israel as a member of the Electrical and Electro-Optical Engineering departments. Dr. Yadid-Pecht founded the VLSI Systems Center at Ben-Gurion University, specializing in CMOS Image Sensors.

Dr. Yadid-Pecht joined the University of Calgary as an iCORE Professor of Integrated Sensors and Intelligent Systems (ISIS) in 2009. She received the IEEE Fellowship in 2007, the SPIE Fellowship in

2015 and the ITHEA International Award in Information and Communication Technologies in 2006.

She is a natural fit for the scope and vision of M Pharmaceutical, Inc., given her work in the areas of integrated CMOS sensors, smart sensors, image processing, neural networks and micro-nano system implementations. Dr. Yadid-Pecht has published over 200 peer reviewed journal and conference papers and has produced more than thirty patents. Among her seminal pieces was co-authoring and co-editing

the first book on CMOS Image Sensors: “CMOS Imaging: From Photo-transduction to Image Processing”, which was published in 2004.

Dr. Yadid-Pecht has served as an Associate Editor for several IEEE journals. She has also served in the IEEE Circuits and Systems Society Board of Governors, was the IEEE Sensors Council VP Publications in 2011 and was an IEEE distinguished lecturer in 2006. She was also the general chair of the IEEE International Conference on Electronic Circuits and Systems (ICECS) and is currently a member of the steering committee of the conference. Dr. Yadid-Pecht also serves as a director on the board of two companies.

"Our goal is to build out our line of biomedical technologies backed by the best people in the business and Dr. Yadid-Pecht certainly fits the bill," added Dr. Mintchev.

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

For more information contact:

Investor Relations                                                                    E:

P: 604.428.0511                                                                      W:

Forward Looking Statements:

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on and such factors as the Company failing to complete the commercialization of the eMosquito, Trimeo and Trimtec biomedical technologies.

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.